Patents for C12Q 1 - Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions (300,231)
08/2006
08/17/2006WO2006085746A2 Diagnosis of metastases in hnscc tumours
08/17/2006WO2006085733A1 Polynucleotide associated with breast cancer comprising single nucleotide polymorphism, microarray and diagnostic kit comprising the same and method for diagnosing breast cancer using the same
08/17/2006WO2006085684A2 Method of diagnosing bladder cancer
08/17/2006WO2006085668A1 Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
08/17/2006WO2006085654A1 Method, reagent and kit for quantifying cholesterol in remnant-like lipoprotein (rlp)
08/17/2006WO2006085648A1 Novel narcolepsy-related gene
08/17/2006WO2006085616A1 Method for amplification of nucleotide sequence
08/17/2006WO2006085612A1 Method for preparation of neural stem cells
08/17/2006WO2006085587A1 Neurosphere-forming agent
08/17/2006WO2006085509A1 Modified pyrroloquinolinequinone-dependent glucose dehydrogenase having excellent substrate-specificity
08/17/2006WO2006085476A1 Method of preparing probe dna for nucleic acid coding for membrane protein, method of detecting expression of gene coding for membrane protein, and carrier for probe dna immobilization
08/17/2006WO2006085411A1 Novel adjuvant for evoking immune responce and utilization of the same
08/17/2006WO2006085407A1 Method for screening gene associated with hcv level
08/17/2006WO2006085402A1 Method of determining resistance to development of bovine leukemia
08/17/2006WO2006085318A2 Laminating apparatus for tti-labels combined with cutting and applying the same
08/17/2006WO2006085196A1 Fatty acid amide hydrolase assay
08/17/2006WO2006085065A2 Vagal afferent neurons as targets for treatment
08/17/2006WO2006085027A2 Medium for the specific detection of resistant organisms
08/17/2006WO2006085009A1 Method for the high-speed detection and/or measurement of a lipase or phospholipase activity
08/17/2006WO2006084937A1 Method for diagnosing and treating women with increased response to hormonal replacement therapy
08/17/2006WO2006084758A1 Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype
08/17/2006WO2006084699A1 New methylation marker
08/17/2006WO2006084648A1 Method for differentiating a xiii factor and fibrinogen deficiency states by means of thrombelastographic engineering
08/17/2006WO2006084552A1 Method for identifying germs
08/17/2006WO2006084457A1 Method and array for the replication and analysis of nucleic acids
08/17/2006WO2006084387A1 Kallikrem 6 in the diagnosis of breast cancer
08/17/2006WO2006084352A1 Novel omega-3 fatty acid desaturase family members and uses thereof
08/17/2006WO2006084340A1 Solid phase assay for methylation analysis
08/17/2006WO2006065940A9 Identification and use of prognostic and predictive markers in cancer treatment
08/17/2006WO2006063704A3 Single nucleotide polymorphism (snp) associated to type ii diabetes
08/17/2006WO2006055521A9 Tirf single molecule analysis and method of sequencing nucleic acids
08/17/2006WO2006047125A3 Method for immobilizing molecular probes to a semiconductor oxide surface
08/17/2006WO2006040154A3 Prokaryotic two hybrid system
08/17/2006WO2006039135A3 Irta-4 antibodies and their uses
08/17/2006WO2006032859A3 Treatment of schizophrenia or suicidal behaviour with a 5-ht2c receptor antagonist
08/17/2006WO2006031815A3 Methods and compositions for proximity assays
08/17/2006WO2006026027A8 Markers of alterations in the y chromosome and uses therefor
08/17/2006WO2006022944A3 Lentiviral vectors and uses thereof
08/17/2006WO2006021892A3 Hm74 and hm74a in cuboidal endothelial cells as associated with inflammation
08/17/2006WO2006017549A3 Cell-based kinase assay
08/17/2006WO2006010161A3 In vitro wound healing assay and device
08/17/2006WO2006007479A3 Method for enumerating mammalian cell micronuclei via differential staining
08/17/2006WO2006007377A3 Methods of screening for bridge-1-mediated disorders, including type ii diabetes
08/17/2006WO2006005718A3 Novel sequence for improving expression of nucleic acid
08/17/2006WO2005123961A3 Approaches to identifying mutations associated with hereditary nonpolyposis colorectal cancer
08/17/2006WO2005114173A3 Hdm2-inhibitor complexes and uses thereof
08/17/2006WO2005113817A9 Aptamer-nanoparticle conjugates and method of use for target analyte detection
08/17/2006WO2005108612A3 Nanoscale biosensor device, system and technique
08/17/2006WO2005108606A3 Method of examining the functional genic variability of hiv and kit for implementing same
08/17/2006WO2005106039A8 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
08/17/2006WO2005087953A3 Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
08/17/2006WO2005086674A3 Brhf1 as a cancer diagnostic marker
08/17/2006WO2005067650A3 Gene expression profiles and methods of use
08/17/2006WO2005067640A3 Methods for enhanced detection & analysis of differentially expressed genes using gene chip microarrays
08/17/2006WO2005060656A3 Identification of a gene expression profile that differentiates ischemic and nonischemic cardiomyopathy
08/17/2006WO2005059517A3 Toll-like receptor assays
08/17/2006WO2005056768A3 Methods of designing, synthesizing, and propagating reference nucleic acids
08/17/2006WO2005043117A3 Gel-shell beads with adsorbed or bound biomolecules
08/17/2006WO2005040489A3 Fluorescent through-bond energy transfer cassettes based on xanthine and pyronin derivatives
08/17/2006WO2005033327A3 Methods and compositions for the diagnosis of sepsis
08/17/2006WO2005017177A3 Modulators of nod1 signaling
08/17/2006WO2004097371A3 System and method for the detection of analytes
08/17/2006WO2004089284A8 Targets for tumor growth inhibition
08/17/2006WO2004037160A3 In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound
08/17/2006WO2004013346A3 Methods and compositions for genotyping
08/17/2006WO2003088904A3 Screening and therapeutic methods for treating circadian rhythm disorders
08/17/2006WO2003066831A3 Angiogenesis genes
08/17/2006US20060185026 Atypical protein kinase c isoforms in disorders of the nervous system and cancer
08/17/2006US20060183991 Polymorphisms in the th clcn7 gene as genetic markers for bone mass
08/17/2006US20060183891 Delta 4,5 glycuronidase nucleic acid compositions
08/17/2006US20060183885 Oncogenic protein for use in identifying modulators which inhibit protein/protein interaction
08/17/2006US20060183805 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
08/17/2006US20060183789 Methods for preventing and treating obesity in patients with mc4 receptor mutations
08/17/2006US20060183757 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
08/17/2006US20060183735 Methods for identifying compounds for regulating muscle mass or function using dopamine receptors
08/17/2006US20060183713 Compositions of low molecular weight heparin produced with modified heparinase III
08/17/2006US20060183701 Methods and compositions for determining non-specific cytotoxicity of a transfection agent
08/17/2006US20060183700 Cgrp binding nucleic acids
08/17/2006US20060183695 Methods of increasing endogenous erythropoietin (EPO)
08/17/2006US20060183686 Thrombin-activatable fibrinolysis inhibitors (TAFI) enzyme molecules; inhibit the breakdown of blood clots, for use in treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease
08/17/2006US20060183664 Pharmaceutical composition for delayed hypersensitivity
08/17/2006US20060183212 Thermostable luciferases and methods of production
08/17/2006US20060183207 Derived from Pyrococcus furious; structure-specific cleavage agents and polymerases for the cleavage and modification of nucleic acids
08/17/2006US20060183204 Reacting a nucleoside triphosphate with a periodate and amine compound and sodium borohydride, attaching label, a protein, an enzyme, a fatty acid, and a peptide, producing nucleic acid (DNA or RNA) fragments enzymatically extended with morpholino-nucleoside triphosphates; dna polymerases
08/17/2006US20060183192 Modulation of sodium channels in dorsal root ganglia
08/17/2006US20060183189 Regulatable gene expression in mammalian cells and mammals
08/17/2006US20060183186 Gene expression profiles in stomach cancer
08/17/2006US20060183183 Instrument that generates a multi-angle light scattering profile of the biological indicator; B. subtilis or B. stearothermophilus spore; adsorbent filter, a membrane, a matrix, glass, plastic, or metal support; radiation , gas plasma , steam or dry heat sterilization treatment
08/17/2006US20060183182 Enzyme substrate
08/17/2006US20060183181 Methods and compositions for the detection and/or quantification of gram positive bacterial contaminants
08/17/2006US20060183180 Viewing attention deficit disorder as protein degradation defect and treat via trypsin, protease, chymotrypsin and/or pancreatic enzyme digestion
08/17/2006US20060183179 Method for quantitatively determining LDL cholesterols
08/17/2006US20060183178 Using chromatographic separation and light scattering to identify and classify stable glucose oxidase formulations; glucose sensors; treating diabetes
08/17/2006US20060183177 For detection of caspases, trypsin and tryptase; comprises luciferase and amino-modified aminoluciferin or a carboxy-terminal protected derivative; solid phase synthesis
08/17/2006US20060183176 Method and reagent for detecting cell death
08/17/2006US20060183172 based in part on the discovery that potato carboxypeptidase inhibitor (PTCI) binds to both TAFIa and TAFIai but not to the 60 kD proenzyme form of TAFI nor to the N-terminal activation peptide of TAFI
08/17/2006US20060183164 IDENTIFYING AN ALLOSTERIC MODULATOR/ANTAGONIST OF G-PROTEIN COUPLED RECEPTORS FOR TREATMENT OF METABOLIC DISORDERS and diseases that have been linked to overactive GPCRs, because traditional neutral-antagonists will not block abnormal ligand-independent activity of these receptors
08/17/2006US20060183163 Methods and compositions for screening for modulators of IgE synthesis, secretion and switch rearrangement
08/17/2006US20060183162 Novel markers for alternatively activated macrophages
08/17/2006US20060183160 Novel beta-secretase and modulation of beta-secretase activity